Related Experiment Videos
Neoantigen Discovery in Human Cancers
1From the Institute for Genomic Medicine, Nationwide Children's Hospital, and The Ohio State University College of Medicine, Columbus, OH.
Abstract:
Cancer is caused by alterations to DNA that ultimately are translated into altered proteins with unique amino acid sequences when compared with their counterparts in normal cells. By inference, these altered proteins have the potential to elicit immune responses such as T-cell recognition, if properly presented by the immune system following protein degradation and major histocompatibility complex binding. Historically, identifying tumor-specific mutant antigens was painstaking work that involved molecular cloning and immune screening. This scenario has changed dramatically in the last few years as new sequencing technology combined with computational data analysis can identify the unique tumor peptide sequences, and algorithmic evaluation of these novel peptides can estimate their binding affinity to the major histocompatibility complex haplotypes encoded by each genome. This process can identify unique neoantigens in each cancer, either as a means of characterizing the overall neoantigen load or as a precursor to designing a personalized cancer vaccine. An overview of the data and analysis methods used to identify cancer neoantigens will be presented along with an in-depth consideration of the nuances of each step.
Insights
New sequencing and computational methods enable the identification of unique cancer neoantigens. These tumor-specific targets can be used to characterize cancer neoantigen load or develop personalized cancer vaccines.
Area of Science:
- Oncology
- Immunology
- Bioinformatics
Background:
- Cancer arises from DNA alterations, leading to unique proteins in tumor cells.
- These altered proteins can trigger immune responses, like T-cell recognition, if presented by the immune system.
- Historically, identifying tumor-specific antigens was a laborious process.
Purpose of the Study:
- To present an overview of data and analysis methods for identifying cancer neoantigens.
- To discuss the nuances and advancements in neoantigen discovery.
- To highlight the role of neoantigens in characterizing cancer and developing personalized vaccines.
Main Methods:
- Utilizing next-generation sequencing technology to identify tumor-specific peptide sequences.
- Employing computational data analysis for processing sequencing information.
- Applying algorithmic evaluation to estimate peptide binding affinity to major histocompatibility complex (MHC) haplotypes.
Main Results:
- Modern techniques allow for rapid identification of unique neoantigens in individual cancers.
- Computational analysis can predict the immunogenic potential of these neoantigens.
- Neoantigen identification serves as a precursor for personalized cancer vaccine design.
Conclusions:
- Advancements in sequencing and bioinformatics have revolutionized neoantigen discovery.
- Neoantigen profiling offers insights into tumor immunogenicity and aids in personalized therapy development.
- The identification of neoantigens is crucial for the future of precision oncology and vaccine development.